GlassScriptPhysician profile
Vashist Nobbee
NPI 1265411573
$5,772.65
in general payments reported to CMS, 2019-2025
36 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $511 · 2021: $676 · 2022: $753 · 2023: $1,035 · 2024: $988 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,761.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $690.08 | 2021-2025 | |
| Amgen INC. | $635.41 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $417.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $273.82 | 2019-2025 | |
| Exact Sciences Corporation | $216.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $167.01 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $152.84 | 2019-2025 | Shingrix |
| Amarin Pharma, INC. | $152.09 | 2019-2021 | |
| Dexcom, INC. | $138.20 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $116.96 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $110.85 | 2021-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $110.01 | 2020-2022 | |
| Abbott Laboratories | $87.37 | 2020-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $83.77 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.43 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $68.38 | 2021-2022 | |
| Eisai INC. | $62.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.34 | 2023-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $40.21 | 2022 | |
| Mannkind Corporation | $34.85 | 2025 | |
| Paratek Pharmaceuticals, INC. | $33.71 | 2025 | Nuzyra, Xhance |
| Scpharmaceuticals INC. | $30.56 | 2025 | |
| Bioventus LLC | $22.12 | 2023 | Gelsyn-3 |
| Xeris Pharmaceuticals, INC. | $20.91 | 2023 | Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.65 | 2025 | Xifaxan |
| Genentech USA, INC. | $19.95 | 2021 | |
| The Binding Site INC. | $18.58 | 2025 | Freelite |
| Dynavax Technologies Corporation | $18.45 | 2023 | Heplisav-B |
| Currax Pharmaceuticals LLC | $17.29 | 2023 | Contrave |
| Allergan, INC. | $15.35 | 2020 | |
| Horizon Therapeutics Plc | $15.34 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.07 | 2022 | |
| Merck Sharp & Dohme LLC | $13.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vashist Nobbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.